Back to mobile site

Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline

April 1, 2026 5:41 PM EDT Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $220.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login